Vaxart (NASDAQ:VXRT) jumps 64% premarket on robust volume in reaction to its agreement with Emergent BioSolutions (NYSE:EBS)
under which the latter will deploy its molecule-to-market contract
development and manufacturing services for Vaxart’s COVID-19 oral
vaccine candidate.
Development services will begin immediately.
Emergent expects to produce enough cGMP vaccine to allow Vaxart to
initiate a Phase 1 study early in H2.
Financial terms are not disclosed.
https://seekingalpha.com/news/3552824-vaxart-up-64-premarket-on-coronavirus-vaccine-deal
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.